Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of heart failure.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2014

Lymperopoulos Anastasios, French Faren

Abstract excerpt

The combination of angiotensin-converting enzyme (ACE) inhibitors and β-adrenergic receptor (βAR) blockers remains the essential component of heart failure (HF) pharmacotherapy. However, individual patient responses to these pharmacotherapies vary widely. The variability in response cannot be explained entirely by clinical characteristics, and genetic variation may play a role. The purpose of this chapter is to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Angiotensin-Converting Enzyme Inhibitors
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Peptidyl-Dipeptidase A

Share to Pharmacogenetics

Share to Receptors, Adrenergic, beta

Share to Treatment Outcome

Source

Identifiers

PMID: 25150872
DOI: 10.1007/978-1-4939-0956-8_10

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of heart failure.PMID 25150872Read ↗

Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.Semantic proximity Read ↗

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read ↗

Pharmacogenetics of heart failure.Semantic proximity Read ↗

Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.Semantic proximity Read ↗

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Semantic proximity Read ↗

Exploring the Role of Genetic and Genomic Factors in Therapeutic Response to Heart Failure: A Comprehensive Analytical ReviewSemantic proximity Read ↗

State of play of pharmacogenetics and personalized medicine in heart failure.Semantic proximity Read ↗

Heart failure pharmacogenetics: past, present, and future.Semantic proximity Read ↗

β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis.Semantic proximity Read ↗

Pharmacogenetics in heart failure: how it will shape the future.Semantic proximity Read ↗

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.Semantic proximity Read ↗

Genetics and pharmacogenetics in heart failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.